The Cambridge neuroscience company, which targets mitochondrial dysfunction
NRG Therapeutics has raised €79M across 3 funding rounds from 9 investors, most recently a Series B round in Sep 2025. Based in Cambridge, UK; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-09-09 | Series B | €58M | Brandon Capital,British Business Bank,Criteria Bio Ventures,M Ventures,Novartis Venture Fund,Omega Funds+1 more | View deal → |
| 2022-11-09 | Series A | €18M | Brandon Capital,Omega Funds,Virtual Biotech | View deal → |
| 2022-06-03 | Other | €3.1M | Biomedical Catalyst award | View deal → |
